{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T22:57:08Z","timestamp":1792277828178,"version":"4.4.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,10,5]]},"DOI":"10.1038\/s41416-026-03515-w","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T21:16:56Z","timestamp":1783027016000},"page":"1051-1056","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of a novel oral anti-vasculogenic mimicry agent, CVM-1118, in advanced well-differentiated neuroendocrine tumors: a Phase IIa trial"],"prefix":"10.1038","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8744-6248","authenticated-orcid":false,"given":"Chia-Jui","family":"Yen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Huang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Yang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7739-4077","authenticated-orcid":false,"given":"Li-Yuan","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jen-Shi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5547-409X","authenticated-orcid":false,"given":"Jason Chia-Hsun","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Hsuan","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I-Chen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0252-3969","authenticated-orcid":false,"given":"Yen-Ling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Man","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4412-4377","authenticated-orcid":false,"given":"Ting-Yu","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Wen","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Du-Shieng","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"3515_CR1","first-page":"471","volume":"68","author":"M Cives","year":"2018","unstructured":"Cives M, Strosberg JR. Gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin. 2018;68:471\u201387.","journal-title":"CA Cancer J Clin"},{"key":"3515_CR2","doi-asserted-by":"publisher","first-page":"10615","DOI":"10.1007\/s13277-014-2612-7","volume":"35","author":"O Abdel-Rahman","year":"2014","unstructured":"Abdel-Rahman O. Vascular endothelial growth factor (VEGF) pathway and neuroendocrine neoplasms (NENs): prognostic and therapeutic considerations. Tumor Biol. 2014;35:10615\u201325.","journal-title":"Tumor Biol"},{"key":"3515_CR3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ejca.2022.12.031","volume":"182","author":"S Das","year":"2023","unstructured":"Das S, Phillips S, Lee CL, Agarwal R, Bergsland E, Strosberg J, et al. Efficacy and toxicity of anti-vascular endothelial growth receptor tyrosine kinase inhibitors in patients with neuroendocrine tumours\u2013a systematic review and meta-analysis. Eur J Cancer. 2023;182:43\u201352.","journal-title":"Eur J Cancer"},{"key":"3515_CR4","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/sj.bjc.6602245","volume":"92","author":"A Couvelard","year":"2004","unstructured":"Couvelard A, O\u2019Toole D, Turley H, Leek R, Sauvanet A, Degott C, et al. Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression. Br J Cancer. 2004;92:94\u2013101.","journal-title":"Br J Cancer"},{"key":"3515_CR5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13045-020-00858-6","volume":"13","author":"Q Luo","year":"2020","unstructured":"Luo Q, Wang J, Zhao W, Peng Z, Liu X, Li B, et al. Vasculogenic mimicry in carcinogenesis and clinical applications. J Hematol Oncol. 2020;13:19.","journal-title":"J Hematol Oncol"},{"key":"3515_CR6","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1159\/000289569","volume":"91","author":"K Villaume","year":"2010","unstructured":"Villaume K, Blanc M, Gouysse G, Walter T, Couderc C, Nejjari M, et al. VEGF secretion by neuroendocrine tumor cells is inhibited by octreotide and by inhibitors of the PI3K\/AKT\/mTOR pathway. Neuroendocrinology. 2010;91:268\u201378.","journal-title":"Neuroendocrinology"},{"key":"3515_CR7","doi-asserted-by":"crossref","unstructured":"Williamson SC, Metcalf RL, Trapani F, Mohan S, Antonello J, Abbott B, et al. Vasculogenic mimicry in small cell lung cancer. Nat Commun. 2016; 7.","DOI":"10.1038\/ncomms13322"},{"key":"3515_CR8","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1016\/j.ajpath.2013.02.023","volume":"182","author":"X Chu","year":"2013","unstructured":"Chu X, Gao X, Jansson L, Quach M, Skogseid B, Barbu A. Multiple microvascular alterations in pancreatic islets and neuroendocrine tumors of a Men1 mouse model. Am J Pathol. 2013;182:2355\u201367.","journal-title":"Am J Pathol"},{"key":"3515_CR9","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1530\/ERC-11-0227","volume":"19","author":"P Mayer","year":"2012","unstructured":"Mayer P, Harjung A, Breinig M, Fischer L, Ehemann V, Malz M, et al. Expression and therapeutic relevance of heat-shock protein 90 in pancreatic endocrine tumors. Endocr Relat Cancer. 2012;19:217\u201332.","journal-title":"Endocr Relat Cancer"},{"key":"3515_CR10","doi-asserted-by":"publisher","first-page":"786","DOI":"10.3390\/biom12060786","volume":"12","author":"LA Wengert","year":"2022","unstructured":"Wengert LA, Backe SJ, Bourboulia D, Mollapour M, Woodford MR. TRAP1 chaperones the metabolic switch in cancer. Biomolecules. 2022;12:786 2022.","journal-title":"Biomolecules"},{"key":"3515_CR11","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.gendis.2016.11.003","volume":"4","author":"X Lv","year":"2016","unstructured":"Lv X, Li J, Zhang C, Hu T, Li S, He S, et al. The role of hypoxia-inducible factors in tumor angiogenesis and cell metabolism. Genes Dis. 2016;4:19.","journal-title":"Genes Dis"},{"key":"3515_CR12","doi-asserted-by":"crossref","unstructured":"Zimna A, Kurpisz M. Hypoxia-inducible factor-1 in physiological and pathophysiological angiogenesis: applications and therapies. Biomed Res Int. 2015; 549412.","DOI":"10.1155\/2015\/549412"},{"key":"3515_CR13","doi-asserted-by":"crossref","unstructured":"Shen L, Chen Y-L, Huang C-C, Shyu Y-C, Seftor REB, Seftor EA, et al. CVM-1118 (foslinanib), a 2-phenyl-4-quinolone derivative, promotes apoptosis and inhibits vasculogenic mimicry via targeting TRAP1. Pathol Oncol Res. 2023; 29.","DOI":"10.3389\/pore.2023.1611038"},{"key":"3515_CR14","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1158\/1535-7163.MCT-17-0136","volume":"16","author":"T Wiedmer","year":"2017","unstructured":"Wiedmer T, Blank A, Pantasis S, Normand L, Bill R, Krebs P, et al. Autophagy inhibition improves sunitinib efficacy in pancreatic neuroendocrine tumors via a lysosome-dependent mechanism. Mol Cancer Ther. 2017;16:2502\u201315.","journal-title":"Mol Cancer Ther"},{"key":"3515_CR15","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1038\/s41416-023-02389-6","volume":"129","author":"MJ Egidi","year":"2023","unstructured":"Egidi MJ, Krug S, Haybaeck J, Michl P, Griesmann H. Anti-angiogenic therapy using the multi-tyrosine kinase inhibitor Regorafenib enhances tumor progression in a transgenic mouse model of \u00df-cell carcinogenesis. Br J Cancer. 2023;129:1225\u201337.","journal-title":"Br J Cancer"},{"key":"3515_CR16","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1200\/JCO.2017.35.15_suppl.2580","volume":"35","author":"AW Tolcher","year":"2017","unstructured":"Tolcher AW, Su W-C, Lakhani N, Gutheir J, Melink TJ, Chu YW, et al. Phase I dose escalation study of CVM-1118, a novel anti-vascular mimicry agent, in patients with advanced cancers. J Clin Oncol. 2017;35:2580.","journal-title":"J Clin Oncol"},{"key":"3515_CR17","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","volume":"387","author":"JC Ya,o","year":"2016","unstructured":"Ya,o JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, Phase 3 study. Lancet. 2016;387:968\u201377.","journal-title":"Lancet"},{"key":"3515_CR18","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1009290","volume":"364","author":"JC Yao","year":"2011","unstructured":"Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:514\u201323.","journal-title":"N Engl J Med"},{"key":"3515_CR19","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1056\/NEJMoa1003825","volume":"364","author":"E Raymond","year":"2011","unstructured":"Raymond E, Dahan L, Raoul J-L, Bang Y-J, Borbath I, Lombard-Bohas C, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:501\u201313.","journal-title":"N Engl J Med"},{"key":"3515_CR20","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1200\/JCO.2025.43.4_suppl.652","volume":"43","author":"S Hijioka","year":"2025","unstructured":"Hijioka S, Honma Y, Machida N, Mizuno N, Hamaguchi T, Boku N, et al. A Phase III study of combination therapy with everolimus plus lanreotide versus everolimus monotherapy for unresectable or recurrent gastroenteropancreatic neuroendocrine tumor (JCOG1901, STARTER-NET). J Clin Oncol. 2025;43:652\u2013652.","journal-title":"J Clin Oncol"},{"key":"3515_CR21","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1530\/ERC-20-0492","volume":"28","author":"S Pusceddu","year":"2021","unstructured":"Pusceddu S, Facciorusso A, Giacomelli L, Prinzi N, Corti F, Niger M, et al. Target therapies plus somatostatin analogs in NETs: a network meta-analysis. Endocr Relat Cancer. 2021;28:467\u201379.","journal-title":"Endocr Relat Cancer"},{"key":"3515_CR22","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1056\/NEJMoa2403991","volume":"392","author":"JA Chan","year":"2024","unstructured":"Chan JA, Geyer S, Zemla T, Knopp MV, Behr S, Pulsipher S, et al. Phase 3 trial of cabozantinib to treat advanced neuroendocrine tumors. N Engl J Med. 2024;392:653\u201365.","journal-title":"N Engl J Med"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03515-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03515-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03515-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:14:05Z","timestamp":1789474445000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03515-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,10,5]]}},"alternative-id":["3515"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03515-w","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"assertion":[{"value":"5 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C-JY, Y-YC, L-YB, JC-HH, Y-HS, and I-CW received honoraria for participation in investigator meetings. C-JY, L-YB, and Y-HS also received travel reimbursement in connection with these meetings. C-JY, M-HC, Y-YC, and JC-HH received honoraria for participation in an advisory meeting related to this trial. C-JY also received reimbursement for travel and accommodation expenses related to attendance at scientific conferences. Y-LC, C-MC, T-YC, Y-WC, and D-SC are employees of TaiRx, Inc. and may hold stock or stock options in the company. All other authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The trial was approved by the institutional review board of each of the eight clinical sites (Institutional Review Board, National Cheng Kung University Hospital; Institutional Review Board, Taipei Veterans General Hospital; Institutional Review Board, Chang Gung Medical Foundation; Research Ethics Committee, China Medical University & Hospital; Institutional Review Board, Taichung Veterans General Hospital; Institutional Review Board, Kaohsiung Medical University Chung-Ho Memorial Hospital) and complied with the Declaration of Helsinki, Good Clinical Practice guidelines, and local regulations. The protocol was registered at ClinicalTrials.gov\n                      (\n                      identifier, NCT03600233). Written informed consent was obtained from all participants.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"During the preparation of this work, the authors used ChatGPT to refine language to enhance readability. After using this tool, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication.","order":3,"name":"Ethics","label":"Declaration of generative AI and AI-assisted technologies in the writing process","group":{"name":"EthicsHeading","label":"Ethics"}}]}}